Does Amlodipine Affect Bone Density?
Amlodipine appears to have either a neutral or potentially negative effect on bone health, with evidence suggesting increased fracture risk compared to thiazide diuretics, though the FDA label does not list bone-related adverse effects.
Evidence from Guidelines and Drug Labels
The FDA label for amlodipine 1 does not mention any effects on bone mineral density or fracture risk among its adverse effects or clinical pharmacology. However, guideline-level evidence from a 2021 comprehensive review 2 specifically addresses this question: in a secondary analysis of the ALLHAT study, patients taking chlorthalidone (a thiazide diuretic) had reduced hip or pelvic fracture risk compared to those receiving amlodipine or lisinopril (p = 0.04). This suggests that amlodipine may be associated with relatively higher fracture risk when compared to thiazides.
Research Evidence: Mixed but Concerning Findings
Human Studies
Recent Mendelian randomization analysis 3 found that genetic proxies for calcium channel blockers (CCBs) as a class were associated with increased fracture risk (OR = 1.07,95% CI: 1.03 to 1.12; P = 0.002). This 2023 study provides robust genetic evidence suggesting CCBs may negatively impact bone health.
Interestingly, one 2023 retrospective cohort study 4 found that nifedipine (another CCB) showed protective effects against osteoporosis compared to other CCBs, with an adjusted HR of 0.44 (95% CI: 0.37-0.53). However, this doesn't address amlodipine specifically and may reflect drug-specific differences within the CCB class.
Animal Studies Show Conflicting Results
Multiple animal studies show protective effects of amlodipine on bone:
- In orchidectomized rats, amlodipine increased bone mineral density and improved biomechanical properties 5, 6
- In ovariectomized rats, amlodipine increased femoral calcium and phosphorus content 7
- One study showed amlodipine prevented bone density reduction in hypertensive rats 8
However, one critical study 9 directly compared amlodipine to cilnidipine (an L-/N-type CCB) and found that cilnidipine ameliorated osteoporosis in ovariectomized hypertensive rats while amlodipine did not, suggesting amlodipine lacks bone-protective effects.
Clinical Interpretation
The disconnect between animal studies (showing benefit) and human evidence (showing harm or no benefit) is significant. The most reliable human evidence—the ALLHAT substudy 2 and the Mendelian randomization analysis 3—suggests amlodipine either increases fracture risk or lacks the bone-protective effects seen with thiazides.
Key Caveats:
- The fracture risk may be mediated through orthostatic hypotension and falls rather than direct bone metabolism effects 10
- Individual CCBs may have different effects on bone (as suggested by the nifedipine study 4)
- The animal data may not translate to humans due to different mechanisms of bone loss
Clinical Recommendation
In patients with hypertension who also have osteoporosis, low bone density, or high fracture risk, consider thiazide diuretics over amlodipine as first-line therapy when clinically appropriate 2. If amlodipine is necessary for blood pressure control, ensure adequate fall prevention strategies and bone health optimization (calcium, vitamin D, bone density monitoring). The evidence does not support discontinuing amlodipine solely for bone concerns in patients with well-controlled hypertension, but it should factor into initial drug selection for at-risk patients.